Takako Yanai Takahashi

Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Y. Ohe, Takuhiro Yamaguchi, Y. Uchitomi, 2019, The Lancet. Oncology.

Efficacy of Olanzapine in Addition to Standard Triplet Antiemetic Therapy for Cisplatin-Based Chemotherapy

N. Inui, H. Hashimoto, K. Hori, 2023, JAMA network open.